NSPR Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -435.91% compared to InspireMD's net margin of --. InspireMD's return on equity of -68.55% beat Perspective Therapeutics's return on equity of --.

InspireMD has a consensus price target of --, signalling upside risk potential of 66.08%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than InspireMD, analysts believe Perspective Therapeutics is more attractive than InspireMD.

InspireMD has a beta of 0.985, which suggesting that the stock is 1.474% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

InspireMD has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

InspireMD quarterly revenues are $1.8M, which are larger than Perspective Therapeutics quarterly revenues of --. InspireMD's net income of -$7.9M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, InspireMD's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD is 15.95x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -435.91% compared to InspireMD's net margin of -18.58%. InspireMD's return on equity of -68.55% beat Retractable Technologies's return on equity of -16.83%.

InspireMD has a consensus price target of --, signalling upside risk potential of 66.08%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that InspireMD has higher upside potential than Retractable Technologies, analysts believe InspireMD is more attractive than Retractable Technologies.

InspireMD has a beta of 0.985, which suggesting that the stock is 1.474% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

InspireMD has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

InspireMD quarterly revenues are $1.8M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. InspireMD's net income of -$7.9M is lower than Retractable Technologies's net income of -$1.9M. Notably, InspireMD's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD is 15.95x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -435.91% compared to InspireMD's net margin of -4291.67%. InspireMD's return on equity of -68.55% beat Catheter Precision's return on equity of -65.84%.

InspireMD has a consensus price target of --, signalling upside risk potential of 66.08%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Catheter Precision has higher upside potential than InspireMD, analysts believe Catheter Precision is more attractive than InspireMD.

InspireMD has a beta of 0.985, which suggesting that the stock is 1.474% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

InspireMD has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

InspireMD quarterly revenues are $1.8M, which are larger than Catheter Precision quarterly revenues of $96K. InspireMD's net income of -$7.9M is lower than Catheter Precision's net income of -$4.1M. Notably, InspireMD's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD is 15.95x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -435.91% compared to InspireMD's net margin of -17.98%. InspireMD's return on equity of -68.55% beat Xtant Medical Holdings's return on equity of -35.98%.

InspireMD has a consensus price target of --, signalling upside risk potential of 66.08%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than InspireMD, analysts believe Xtant Medical Holdings is more attractive than InspireMD.

InspireMD has a beta of 0.985, which suggesting that the stock is 1.474% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

InspireMD has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InspireMD pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

InspireMD quarterly revenues are $1.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. InspireMD's net income of -$7.9M is lower than Xtant Medical Holdings's net income of -$5M. Notably, InspireMD's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InspireMD is 15.95x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.